TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Novo Nordisk
Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management

The FDA has approved Wegovy® pill (oral semaglutide 25 mg), the first oral GLP-1 receptor agonist for weight management, showing 16.6% mean weight loss comparable to injectable Wegovy®. The drug is expected to launch in the US in early January 2026. Separately, the EMA issued a positive opinion for a higher 7.2 mg dose showing 20.7% average weight loss. Novo Nordisk also completed its acquisition of Akero Therapeutics.

Insights
TALKW   positive

Positioned in the growing online mental health platforms segment with potential for digital therapy expansion


NVO   positive

FDA approval of first oral GLP-1 therapy for weight management with efficacy comparable to injectable form, positive EMA recommendation for higher dose, and successful completion of Akero Therapeutics acquisition strengthen product portfolio and market position in obesity treatment.